<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Page not found | PREVENT-MINS PROTOCOL</title>
  <meta name="description" content="Protokół badania klinicznego PREVENT-MINS." />
  <meta name="generator" content="bookdown 0.27 and GitBook 2.6.7" />

  <meta property="og:title" content="Page not found | PREVENT-MINS PROTOCOL" />
  <meta property="og:type" content="book" />
  
  <meta property="og:description" content="Protokół badania klinicznego PREVENT-MINS." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Page not found | PREVENT-MINS PROTOCOL" />
  
  <meta name="twitter:description" content="Protokół badania klinicznego PREVENT-MINS." />
  

<meta name="author" content="Ośrodek Intensywnej Terapii i Medycyny Okołozabiegowej Collegium Medicum" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  


<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>




<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="toc-logo"><a href="./"><img src="LOGO.jpg"></a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Skrócony protokół badania</a>
<ul>
<li class="chapter" data-level="1.1" data-path="index.html"><a href="index.html#wstęp-i-uzasadnienie-badania"><i class="fa fa-check"></i><b>1.1</b> Wstęp i uzasadnienie badania</a>
<ul>
<li class="chapter" data-level="1.1.1" data-path="index.html"><a href="index.html#jakie-jest-znaczenie-uszkodzenia-mięśnia-sercowego-po-zabiegu-pozasercowym"><i class="fa fa-check"></i><b>1.1.1</b> Jakie jest znaczenie uszkodzenia mięśnia sercowego po zabiegu pozasercowym?</a></li>
<li class="chapter" data-level="1.1.2" data-path="index.html"><a href="index.html#czy-istnieje-związek-pomiędzy-częstotliwością-akcji-serca-oraz-występowaniem-powikłań-okołozabiegowych"><i class="fa fa-check"></i><b>1.1.2</b> Czy istnieje związek pomiędzy częstotliwością akcji serca oraz występowaniem powikłań okołozabiegowych?</a></li>
<li class="chapter" data-level="1.1.3" data-path="index.html"><a href="index.html#czy-leki-obniżające-częstotliwość-akcji-serca-zmniejszają-częstość-występowania-powikłań-okołozabiegowych"><i class="fa fa-check"></i><b>1.1.3</b> Czy leki obniżające częstotliwość akcji serca zmniejszają częstość występowania powikłań okołozabiegowych?</a></li>
<li class="chapter" data-level="1.1.4" data-path="index.html"><a href="index.html#dlaczego-w-badaniu-prevent-mins-zastosowana-zostanie-iwabradyna"><i class="fa fa-check"></i><b>1.1.4</b> Dlaczego w badaniu PREVENT-MINS zastosowana zostanie iwabradyna?</a></li>
<li class="chapter" data-level="1.1.5" data-path="index.html"><a href="index.html#dlaczego-przeprowadzenie-badania-prevent-mins-jest-istotne"><i class="fa fa-check"></i><b>1.1.5</b> Dlaczego przeprowadzenie badania PREVENT-MINS jest istotne?</a></li>
</ul></li>
<li class="chapter" data-level="1.2" data-path="index.html"><a href="index.html#plan-badania"><i class="fa fa-check"></i><b>1.2</b> Plan badania</a>
<ul>
<li class="chapter" data-level="1.2.1" data-path="index.html"><a href="index.html#cele-badania"><i class="fa fa-check"></i><b>1.2.1</b> Cele badania</a></li>
<li class="chapter" data-level="1.2.2" data-path="index.html"><a href="index.html#projekt-badania"><i class="fa fa-check"></i><b>1.2.2</b> Projekt badania</a></li>
<li class="chapter" data-level="1.2.3" data-path="index.html"><a href="index.html#wielkość-próby"><i class="fa fa-check"></i><b>1.2.3</b> Wielkość próby</a></li>
</ul></li>
<li class="chapter" data-level="1.3" data-path="index.html"><a href="index.html#kryteria-włączenia-i-wyłączenia-z-badania-prevent-mins"><i class="fa fa-check"></i><b>1.3</b> Kryteria włączenia i wyłączenia z badania PREVENT-MINS</a></li>
<li class="chapter" data-level="1.4" data-path="index.html"><a href="index.html#rekrutacja-pacjentów-oraz-świadoma-zgoda-na-udział-w-badaniu"><i class="fa fa-check"></i><b>1.4</b> Rekrutacja pacjentów oraz świadoma zgoda na udział w badaniu</a></li>
<li class="chapter" data-level="1.5" data-path="index.html"><a href="index.html#randomizacja"><i class="fa fa-check"></i><b>1.5</b> Randomizacja</a></li>
<li class="chapter" data-level="1.6" data-path="index.html"><a href="index.html#procedury-przewidziane-w-ramach-badania"><i class="fa fa-check"></i><b>1.6</b> Procedury przewidziane w ramach badania</a></li>
<li class="chapter" data-level="1.7" data-path="index.html"><a href="index.html#interwencje-badawcze"><i class="fa fa-check"></i><b>1.7</b> Interwencje badawcze</a></li>
<li class="chapter" data-level="1.8" data-path="index.html"><a href="index.html#minimalizacja-ryzyka-monitorowanie-oraz-strategia-radzenia-sobie-z-potencjalnymi-problemami"><i class="fa fa-check"></i><b>1.8</b> Minimalizacja ryzyka, monitorowanie oraz strategia radzenia sobie z potencjalnymi problemami</a></li>
<li class="chapter" data-level="1.9" data-path="index.html"><a href="index.html#obserwacja-uczestników-badania"><i class="fa fa-check"></i><b>1.9</b> Obserwacja uczestników badania</a>
<ul>
<li class="chapter" data-level="1.9.1" data-path="index.html"><a href="index.html#hospitalizacja"><i class="fa fa-check"></i><b>1.9.1</b> Hospitalizacja</a></li>
<li class="chapter" data-level="1.9.2" data-path="index.html"><a href="index.html#obserwacja-30-dniowa"><i class="fa fa-check"></i><b>1.9.2</b> Obserwacja 30-dniowa</a></li>
<li class="chapter" data-level="1.9.3" data-path="index.html"><a href="index.html#obserwacja-roczna"><i class="fa fa-check"></i><b>1.9.3</b> Obserwacja roczna</a></li>
</ul></li>
<li class="chapter" data-level="1.10" data-path="index.html"><a href="index.html#punkty-końcowe"><i class="fa fa-check"></i><b>1.10</b> Punkty końcowe</a>
<ul>
<li class="chapter" data-level="1.10.1" data-path="index.html"><a href="index.html#pierwotny-punkt-końcowy"><i class="fa fa-check"></i><b>1.10.1</b> Pierwotny punkt końcowy</a></li>
<li class="chapter" data-level="1.10.2" data-path="index.html"><a href="index.html#drugorzędowe-punkty-końcowe"><i class="fa fa-check"></i><b>1.10.2</b> Drugorzędowe punkty końcowe</a></li>
<li class="chapter" data-level="1.10.3" data-path="index.html"><a href="index.html#trzeciorzędowe-punkty-końcowe"><i class="fa fa-check"></i><b>1.10.3</b> Trzeciorzędowe punkty końcowe</a></li>
</ul></li>
<li class="chapter" data-level="1.11" data-path="index.html"><a href="index.html#analiza-statystyczna"><i class="fa fa-check"></i><b>1.11</b> Analiza statystyczna</a></li>
<li class="chapter" data-level="1.12" data-path="index.html"><a href="index.html#raportowanie-występowania-działań-niepożądanych-oraz-poważnych-działań-niepożądanych"><i class="fa fa-check"></i><b>1.12</b> Raportowanie występowania działań niepożądanych oraz poważnych działań niepożądanych</a></li>
<li class="chapter" data-level="1.13" data-path="index.html"><a href="index.html#pozostałe-kwestie-związane-z-badaniem"><i class="fa fa-check"></i><b>1.13</b> Pozostałe kwestie związane z badaniem</a>
<ul>
<li class="chapter" data-level="1.13.1" data-path="index.html"><a href="index.html#kwestie-etyczne"><i class="fa fa-check"></i><b>1.13.1</b> Kwestie etyczne</a></li>
<li class="chapter" data-level="1.13.2" data-path="index.html"><a href="index.html#zarządzanie-danymi"><i class="fa fa-check"></i><b>1.13.2</b> Zarządzanie danymi</a></li>
<li class="chapter" data-level="1.13.3" data-path="index.html"><a href="index.html#kwestie-związane-z-covid-19"><i class="fa fa-check"></i><b>1.13.3</b> Kwestie związane z COVID-19</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><i class="fa fa-check"></i><b>2</b> Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery</a>
<ul>
<li class="chapter" data-level="2.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#clinical-trial-summary"><i class="fa fa-check"></i><b>2.1</b> CLINICAL TRIAL SUMMARY</a></li>
<li class="chapter" data-level="2.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#introduction-and-rationale"><i class="fa fa-check"></i><b>2.2</b> INTRODUCTION AND RATIONALE</a>
<ul>
<li class="chapter" data-level="2.2.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#principal-research-question"><i class="fa fa-check"></i><b>2.2.1</b> Principal research question</a></li>
<li class="chapter" data-level="2.2.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#the-need-for-prevent-mins-trial"><i class="fa fa-check"></i><b>2.2.2</b> The need for PREVENT-MINS trial</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#plan-of-investigation"><i class="fa fa-check"></i><b>2.3</b> PLAN OF INVESTIGATION</a>
<ul>
<li class="chapter" data-level="2.3.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-objectives"><i class="fa fa-check"></i><b>2.3.1</b> Trial objectives</a></li>
<li class="chapter" data-level="2.3.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-design"><i class="fa fa-check"></i><b>2.3.2</b> Trial design</a></li>
<li class="chapter" data-level="2.3.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#sample-size"><i class="fa fa-check"></i><b>2.3.3</b> Sample size</a></li>
</ul></li>
<li class="chapter" data-level="2.4" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#eligibility-criteria"><i class="fa fa-check"></i><b>2.4</b> ELIGIBILITY CRITERIA</a>
<ul>
<li class="chapter" data-level="2.4.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#inclusion-criteria"><i class="fa fa-check"></i><b>2.4.1</b> Inclusion criteria</a></li>
<li class="chapter" data-level="2.4.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#exclusion-criteria"><i class="fa fa-check"></i><b>2.4.2</b> Exclusion criteria</a></li>
</ul></li>
<li class="chapter" data-level="2.5" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#randomisation"><i class="fa fa-check"></i><b>2.5</b> RANDOMISATION</a></li>
<li class="chapter" data-level="2.6" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-interventions"><i class="fa fa-check"></i><b>2.6</b> TRIAL INTERVENTIONS</a>
<ul>
<li class="chapter" data-level="2.6.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#ivabradine-or-placebo"><i class="fa fa-check"></i><b>2.6.1</b> Ivabradine or placebo</a></li>
</ul></li>
<li class="chapter" data-level="2.7" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#plan-to-minimize-risks-of-monitoring-for-and-approach-to-potential-problems"><i class="fa fa-check"></i><b>2.7</b> PLAN TO MINIMIZE RISKS OF, MONITORING FOR, AND APPROACH TO POTENTIAL PROBLEMS</a>
<ul>
<li class="chapter" data-level="2.7.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#minimising-potential-risks-associated-with-ivabradine-administration"><i class="fa fa-check"></i><b>2.7.1</b> Minimising potential risks associated with ivabradine administration</a></li>
</ul></li>
<li class="chapter" data-level="2.8" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#other-management-at-the-discretion-of-the-attending-physician"><i class="fa fa-check"></i><b>2.8</b> OTHER MANAGEMENT AT THE DISCRETION OF THE ATTENDING PHYSICIAN</a>
<ul>
<li class="chapter" data-level="2.8.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#perioperative-management-of-patients-with-other-indications-for-heart-rate-reducing-drugs"><i class="fa fa-check"></i><b>2.8.1</b> Perioperative management of patients with other indications for heart rate reducing drugs</a></li>
</ul></li>
<li class="chapter" data-level="2.9" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#follow-up"><i class="fa fa-check"></i><b>2.9</b> FOLLOW-UP</a></li>
<li class="chapter" data-level="2.10" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-outcomes"><i class="fa fa-check"></i><b>2.10</b> TRIAL OUTCOMES</a>
<ul>
<li class="chapter" data-level="2.10.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#primary-outcome"><i class="fa fa-check"></i><b>2.10.1</b> Primary outcome</a></li>
<li class="chapter" data-level="2.10.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#secondary-outcomes"><i class="fa fa-check"></i><b>2.10.2</b> Secondary outcomes</a></li>
<li class="chapter" data-level="2.10.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#tertiary-outcomes"><i class="fa fa-check"></i><b>2.10.3</b> Tertiary outcomes</a></li>
</ul></li>
<li class="chapter" data-level="2.11" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#adjudication-of-trial-outcomes"><i class="fa fa-check"></i><b>2.11</b> ADJUDICATION OF TRIAL OUTCOMES</a></li>
<li class="chapter" data-level="2.12" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#data-analyses"><i class="fa fa-check"></i><b>2.12</b> DATA ANALYSES</a>
<ul>
<li class="chapter" data-level="2.12.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#main-analyses"><i class="fa fa-check"></i><b>2.12.1</b> Main Analyses</a></li>
<li class="chapter" data-level="2.12.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#primary-endpoint"><i class="fa fa-check"></i><b>2.12.2</b> Primary endpoint</a></li>
<li class="chapter" data-level="2.12.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#secondary-and-tertiary-endpoint"><i class="fa fa-check"></i><b>2.12.3</b> Secondary and Tertiary endpoint</a></li>
<li class="chapter" data-level="2.12.4" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#interim-analyses"><i class="fa fa-check"></i><b>2.12.4</b> Interim analyses</a></li>
<li class="chapter" data-level="2.12.5" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#missing-data"><i class="fa fa-check"></i><b>2.12.5</b> Missing data</a></li>
<li class="chapter" data-level="2.12.6" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#subgroup-analyses"><i class="fa fa-check"></i><b>2.12.6</b> Subgroup analyses</a></li>
</ul></li>
<li class="chapter" data-level="2.13" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#reporting-of-adverse-events-and-serious-adverse-events"><i class="fa fa-check"></i><b>2.13</b> REPORTING OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS</a>
<ul>
<li class="chapter" data-level="2.13.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#definitions-and-reporting-of-adverse-events-and-serious-adverse-events"><i class="fa fa-check"></i><b>2.13.1</b> Definitions and reporting of adverse events and serious adverse events</a></li>
<li class="chapter" data-level="2.13.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#safety-reporting"><i class="fa fa-check"></i><b>2.13.2</b> Safety reporting</a></li>
</ul></li>
<li class="chapter" data-level="2.14" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#substudies"><i class="fa fa-check"></i><b>2.14</b> SUBSTUDIES</a></li>
<li class="chapter" data-level="2.15" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-management"><i class="fa fa-check"></i><b>2.15</b> TRIAL MANAGEMENT</a>
<ul>
<li class="chapter" data-level="2.15.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#organisational-structure-of-the-prevent--mins-trial"><i class="fa fa-check"></i><b>2.15.1</b> Organisational structure of the PREVENT- MINS trial</a></li>
<li class="chapter" data-level="2.15.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#operations-committees"><i class="fa fa-check"></i><b>2.15.2</b> Operations Committees</a></li>
<li class="chapter" data-level="2.15.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#site-principal-investigators"><i class="fa fa-check"></i><b>2.15.3</b> Site Principal Investigators</a></li>
</ul></li>
<li class="chapter" data-level="2.16" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#other-considerations"><i class="fa fa-check"></i><b>2.16</b> OTHER CONSIDERATIONS</a>
<ul>
<li class="chapter" data-level="2.16.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#ethical-considerations"><i class="fa fa-check"></i><b>2.16.1</b> Ethical considerations</a></li>
<li class="chapter" data-level="2.16.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#data-management"><i class="fa fa-check"></i><b>2.16.2</b> Data management</a></li>
<li class="chapter" data-level="2.16.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#confidentiality-and-unblinded-data"><i class="fa fa-check"></i><b>2.16.3</b> Confidentiality and unblinded data</a></li>
<li class="chapter" data-level="2.16.4" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#emergency-unblinding"><i class="fa fa-check"></i><b>2.16.4</b> Emergency unblinding</a></li>
</ul></li>
<li class="chapter" data-level="2.17" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#importance-of-prevent-mins-trial"><i class="fa fa-check"></i><b>2.17</b> IMPORTANCE OF PREVENT-MINS TRIAL</a></li>
<li class="chapter" data-level="2.18" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-conduct-during-the-covid-19-pandemic"><i class="fa fa-check"></i><b>2.18</b> TRIAL CONDUCT DURING THE COVID-19 PANDEMIC</a>
<ul>
<li class="chapter" data-level="2.18.1" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#subject-visits-and-assessments"><i class="fa fa-check"></i><b>2.18.1</b> Subject Visits and Assessments</a></li>
<li class="chapter" data-level="2.18.2" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#study-drug-supply"><i class="fa fa-check"></i><b>2.18.2</b> Study Drug Supply</a></li>
<li class="chapter" data-level="2.18.3" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#covid-19-exposure"><i class="fa fa-check"></i><b>2.18.3</b> COVID-19 exposure</a></li>
<li class="chapter" data-level="2.18.4" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#on-site-monitoring-visits"><i class="fa fa-check"></i><b>2.18.4</b> On-site Monitoring Visits</a></li>
</ul></li>
<li class="chapter" data-level="2.19" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#references"><i class="fa fa-check"></i><b>2.19</b> REFERENCES</a></li>
<li class="chapter" data-level="2.20" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#prevent-mins-trial-procedure-schedule"><i class="fa fa-check"></i><b>2.20</b> PREVENT-MINS Trial Procedure Schedule</a></li>
<li class="chapter" data-level="2.21" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#trial-flow-chart"><i class="fa fa-check"></i><b>2.21</b> TRIAL FLOW CHART</a></li>
<li class="chapter" data-level="2.22" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#appendix-ii.-prevent-mins-outcome-definitions"><i class="fa fa-check"></i><b>2.22</b> APPENDIX II. PREVENT-MINS Outcome Definitions</a></li>
<li class="chapter" data-level="2.23" data-path="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html"><a href="ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html#appendix-iii.-prevent-mins-sample-size-calculation"><i class="fa fa-check"></i><b>2.23</b> APPENDIX III. PREVENT-MINS Sample Size Calculation</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="euroqol-group-eq-5d-pl.html"><a href="euroqol-group-eq-5d-pl.html"><i class="fa fa-check"></i><b>3</b> EuroQol Group EQ-5D PL</a></li>
<li class="chapter" data-level="4" data-path="asa-ps.html"><a href="asa-ps.html"><i class="fa fa-check"></i><b>4</b> ASA PS</a></li>
<li class="chapter" data-level="5" data-path="duke-activity-status-index-dasi.html"><a href="duke-activity-status-index-dasi.html"><i class="fa fa-check"></i><b>5</b> Duke Activity Status Index (DASI)</a></li>
<li class="chapter" data-level="6" data-path="clinical-frailty-scale-cfs.html"><a href="clinical-frailty-scale-cfs.html"><i class="fa fa-check"></i><b>6</b> Clinical Frailty Scale (CFS)</a></li>
<li class="divider"></li>
<li><a href="https://nauka.cm-uj.krakow.pl/niekomercyjne-badania-kliniczne/" target="blank">Sponsor: CMUJ</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">PREVENT-MINS PROTOCOL</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="page-not-found" class="section level1">
<h1>Page not found</h1>
<p>The page you requested cannot be found (perhaps it was moved or renamed).</p>
<p>You may want to try searching to find the page's new location, or use
the table of contents to find the page you are looking for.</p>
</div>
            </section>

          </div>
        </div>
      </div>


    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
